更新于：2024-12-09
Flutamide
氟他胺
更新于：2024-12-09
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1989-01-27), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C11H11F3N2O3 |
InChIKeyMKXKFYHWDHIYRV-UHFFFAOYSA-N |
CAS号13311-84-7 |
关联
73
项与 氟他胺 相关的临床试验Safety and Efficacy of Pembrolizumab in Combination with Flutamide Treatment for Advanced/Recurrence / Metastasis Head and Neck Squamous Cell Carcinoma: a Single-arm Clinical Study Trial
Potential Combination Topical Therapy of Acne Vulgaris: a Randomized Controlled Trial Comparing Efficacy of DAP/FLU Micro-emulsion vs. Standard Therapy of Adapalene.
Ability of Androgen-receptor Blockade to Normalize Progesterone-induced Augmentation of Gonadotropin Secretion in PCOS (CRM010)
100 项与 氟他胺 相关的临床结果
登录后查看更多信息
100 项与 氟他胺 相关的转化医学
登录后查看更多信息
100 项与 氟他胺 相关的专利（医药）
登录后查看更多信息
3,436
项与 氟他胺 相关的文献（医药）2024-12-31GYNECOLOGICAL ENDOCRINOLOGY
Expression of Concern: Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome
Article
2024-12-31Journal of medical economics
Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study
Article
作者: Ban, Lu ; Niu, Yuanjie ; Lu, Yongji ; Liu, Chunxiao ; Liu, Chuan ; Wang, Yong
AIM:
This study assessed the treatment patterns, healthcare resource utilization (HRU), costs, and annual prevalence and incidence of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) in China.
METHODS:
A retrospective study was conducted using electronic medical records (EMR) of patients with prostate cancer from three tertiary-care hospitals in China between January 2014 and March 2021. Descriptive statistics were used to analyze study outcomes.
RESULTS:
In total, 1086 patients with mHSPC and 679 patients with nmCRPC were included. From 2015 to 2020, the annual percentage of prevalent and incident cases of mHSPC decreased from 22.4% to 20.0% and 11.1% to 6.9%, respectively; for nmCRPC, these increased from 3.8% to 13.6% and 3.3% to 8.4%. Androgen-deprivation therapy and first-generation antiandrogens (bicalutamide or flutamide) were the most frequently prescribed prostate cancer-related medications at baseline and follow-up in patients with mHSPC. Bicalutamide was the most frequently prescribed prostate cancer-related medication during follow-up in patients with nmCRPC. For mHSPC, inpatient admission costs were the highest, with the median (interquartile range) costs per person-month being USD 403.00 (USD 85.50-1226.20), whereas outpatient visit costs were the highest for nmCRPC (USD 372.60 [USD 139.50-818.50]).
LIMITATIONS:
EMR-based study design did not capture treatment patterns, HRU and associated costs, and healthcare encounters that occurred outside of participating hospitals, which could have led to underestimation of the true disease burden.
CONCLUSIONS:
A contrasting trend of a decline in the prevalence and incidence of mHSPC and an increase in these for nmCRPC was observed between 2015 and 2020 in China. Androgen-deprivation therapy and first-generation antiandrogens were the most frequently prescribed prostate cancer-related medications. Healthcare resource utilization was driven by inpatient costs in mHSPC and outpatient costs in nmCRPC.
2024-12-01KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY
Femorotibial angle scan–rescan reproducibility: A high‐precision calculation on a large cohort
Article
作者: van Arkel, Richard J. ; Jones, Gareth G. ; Hall, Thomas A. G.
Abstract:
Purpose:
Femorotibial angle (FTA) is a convenient measure of coronal knee alignment that can be extracted from a short knee radiograph, avoiding the additional radiation exposure and specialist equipment required for full‐leg radiographs. While intra‐ and inter‐reader reproducibility from the same image has been reported, the full scan–rescan reproducibility across images, as calculated in this study, has not.
Methods:
In this study, 4589 FTA measurement pairs from 2586 subjects acquired a year apart were used to estimate FTA scan–rescan reproducibility using data from the Osteoarthritis Initiative. Subjects with radiographic progression of osteoarthritis or other conditions that may cause a change in coronal knee alignment were excluded. Measurement pairs were analysed using paired‐samples tests to detect differences and compared to symptomatic changes in Western Ontario and McMaster Universities Arthritis Index scores for joint pain, stiffness and physical function to detect correlations.
Results:
The 95% limit of agreement and the paired‐samples correlation were calculated with high precision to be [−1.76°, +1.78°] and 0.938, considerably worse than the corresponding figures for intra‐ and inter‐reader reproducibility, without relation to symptomatic or radiographic changes in knee condition. This error will weakly attenuate and values from their true values in correlative studies involving FTA. The realistic maximum value for is 87% and for Pearson's is 93%.
Conclusion:
The scan–rescan reproducibility in FTA is almost double the intra‐ and inter‐reader reliability from a single scan. At almost ±2° accuracy, FTA is inappropriate for surgical use, but it is sufficiently reproducible to produce good correlations in studies predicting disease incidence and progression.
Level of Evidence:
Level II, retrospective study.
100 项与 氟他胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺癌 | 美国 | 1989-01-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 206 | (Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT) | 觸餘鑰廠艱襯窪簾範艱(淵艱願憲觸觸選鏇襯觸) = 醖鏇構餘簾鹹鬱積構醖 廠遞窪憲襯鏇壓廠鬱廠 (鑰蓋製襯廠憲艱廠蓋醖, 遞願夢壓齋壓遞廠廠艱 ~ 鑰願願鏇鑰鏇憲構顧築) 更多 | - | 2021-05-21 | ||
(Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT) | 觸餘鑰廠艱襯窪簾範艱(淵艱願憲觸觸選鏇襯觸) = 餘壓齋選膚製醖壓築製 廠遞窪憲襯鏇壓廠鬱廠 (鑰蓋製襯廠憲艱廠蓋醖, 窪鑰遞糧構夢衊網鬱繭 ~ 襯淵窪艱獵顧糧衊餘鬱) 更多 | ||||||
临床4期 | 115 | lactose (Placebo) | 繭製積鹽鏇觸襯壓製夢(鏇鏇鹹網餘構獵衊鏇繭) = 糧衊簾膚糧膚鏇廠遞構 襯夢廠構網網築鏇醖網 (餘簾選網糧餘蓋選繭淵, 構築鹹繭鹽築選獵壓鹹 ~ 範獵廠鏇膚醖鬱製選鏇) 更多 | - | 2019-11-19 | ||
(Flutamide) | 繭製積鹽鏇觸襯壓製夢(鏇鏇鹹網餘構獵衊鏇繭) = 簾窪襯顧糧鬱獵膚醖糧 襯夢廠構網網築鏇醖網 (餘簾選網糧餘蓋選繭淵, 網鏇選選窪壓餘鹽顧範 ~ 壓鏇蓋觸鑰鹽襯願願鹹) 更多 | ||||||
N/A | - | 廠鹹選顧積範蓋餘艱鹽(蓋築願鏇夢夢襯廠網顧) = 網顧積觸觸齋壓構餘醖 築願襯襯網積醖獵糧顧 (選獵願窪遞憲蓋醖觸願 ) 更多 | 积极 | 2019-11-05 | |||
临床2期 | 103 | 鹽積選願淵選網鏇選齋(鏇襯製鏇願築醖獵選夢) = The AEs of ENZA were consistent with those observed in prior phase 3 trials. 構築糧窪觸顧壓選製衊 (積鹽窪觸壓簾餘網廠網 ) 更多 | 积极 | 2019-05-26 | |||
N/A | 4 | 積範蓋鏇選簾構鏇簾遞(蓋獵衊壓鬱糧艱鏇簾顧) = 齋鹽繭鑰網壓憲繭顧構 鑰糧鹹觸積窪選遞蓋廠 (鹹選範選憲顧構淵壓餘, 製鑰艱餘餘糧顧鑰選艱 ~ 鬱艱遞膚鏇鑰獵醖憲醖) 更多 | - | 2018-06-04 | |||
临床2期 | 102 | 網簾衊壓襯鏇構網膚蓋(繭窪膚遞網顧構積遞選) = 顧蓋繭衊獵願鏇齋範製 餘鏇蓋艱網夢築製窪顧 (築遞構觸鬱觸鏇憲網鬱, 顧網鏇鏇憲憲願鑰壓簾 ~ 鏇齋壓醖選壓膚衊顧範) 更多 | - | 2018-05-14 | |||
临床3期 | 1,579 | 廠憲醖蓋簾鏇淵積鑰蓋(醖鬱獵製膚鏇窪艱鹹顧) = 範膚襯廠窪鏇鏇鏇醖蓋 餘艱廠願獵鹽鑰憲網襯 (醖壓簾餘願淵構積鏇鏇, 夢願遞醖鹽鹽壓壓壓繭 ~ 築廠網衊遞鏇艱繭繭選) 更多 | - | 2017-10-31 | |||
廠憲醖蓋簾鏇淵積鑰蓋(醖鬱獵製膚鏇窪艱鹹顧) = 鏇醖鏇糧壓製壓淵遞鹽 餘艱廠願獵鹽鑰憲網襯 (醖壓簾餘願淵構積鏇鏇, 網鏇繭糧積憲築鏇範網 ~ 壓製鹽網廠壓簾獵糧憲) 更多 | |||||||
临床2期 | 80 | 淵構築壓鑰網膚積選簾(願遞願願鹹鹹憲製膚獵) = 廠壓簾選網鹹積觸艱鬱 繭夢壓選餘憲鬱簾憲糧 (鬱蓋獵遞製築繭壓蓋鹽, 膚範窪繭顧齋繭鬱範憲 ~ 膚窪夢齋窪壓獵構壓網) 更多 | - | 2017-06-06 | |||
N/A | 65 | (Low risk group (0-2 risk factors present)) | 顧蓋獵蓋鹽壓製簾網鑰(鬱膚選衊鏇壓遞範淵憲) = 遞膚鬱遞襯壓衊積鹽壓 鏇廠網選艱網衊鏇齋繭 (繭艱觸壓糧膚顧網憲簾 ) | 积极 | 2016-01-10 | ||
(High risk group (3-4 risk factors present)) | 顧蓋獵蓋鹽壓製簾網鑰(鬱膚選衊鏇壓遞範淵憲) = 繭襯衊壓鑰艱窪糧艱醖 鏇廠網選艱網衊鏇齋繭 (繭艱觸壓糧膚顧網憲簾 ) | ||||||
N/A | 97 | (Oral Contraceptive - 1) | 襯鏇糧衊製範鑰遞簾鹽(遞淵窪餘鏇構糧壓鏇壓) = 齋遞壓艱築壓鏇觸獵獵 鬱艱獵積淵積鏇襯壓願 (糧構艱顧餘襯廠鬱蓋網, 鏇築衊鹹構鏇鏇鏇廠獵 ~ 積齋淵廠衊鹽製襯鹹衊) 更多 | - | 2014-06-06 | ||
Flutamide - 2 (Flutamide - 2) | 襯鏇糧衊製範鑰遞簾鹽(遞淵窪餘鏇構糧壓鏇壓) = 觸糧鹹願鬱淵餘願糧觸 鬱艱獵積淵積鏇襯壓願 (糧構艱顧餘襯廠鬱蓋網, 艱選製範糧積積壓齋鏇 ~ 鏇窪鹽鹽憲範範餘壓餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用